LabLogic helps drive European innovation in At-211 Targeted Alpha Therapy
04/06/2026
LabLogic’s R&D Director Dr Tom Deakin and R&D Physicist Dr Katie Staunton-Mann (back row, second and third from left) at last year’s αccelerate.EU consortium ahead of the EANM 2025 Annual Congress in Barcelona.
A newly published editorial has highlighted the need for coordinated action to overcome clinical and regulatory challenges
Published in the European Journal of Nuclear Medicine and Molecular Imaging, the paper entitled 211At Targeted Alpha Therapy in Europe: Overcoming Clinical, Regulatory, and Infrastructure Challenges outlines the immense potential of astatine-211 as a new therapeutic radionuclide and calls for a coordinated approach to overcome barriers to clinical adoption.
Supported by the Innovative Health Initiative Joint Undertaking, αccelerate.EU is a European initiative to translate 211At-based radiopharmaceuticals from research activity to first stage clinical trials for three challenging cancers by the end of 2029. LabLogic is one of 17 partners, with others joining from industry and academia.
Building the foundations for the future of targeted alpha therapy
Targeted alpha therapy using isotopes such as 211At is a promising new development in cancer treatments. By delivering highly potent alpha radiation directly to cancer cells, TAT has the potential to treat disease while minimising damage to surrounding healthy tissue.
However, the paper identifies several challenges associated with 211At that continue to limit the widespread adoption of alpha therapies, including radionuclide supply, radiopharmaceutical development, generation of clinical evidence, and recognised regulatory frameworks.
LabLogic's role within αccelerate.EU
The editorial highlighted the importance of establishing harmonised approaches for regulatory compliance and scalable production. As a specialist manufacturer of instrumentation for quality control, LabLogic is helping to develop and standardise regulatory frameworks that ensure 211At-based radiopharmaceuticals can be administered safely in addition to innovating new hardware and software solutions specifically for this emerging application.
For LabLogic, participation in the programme reflects a continued commitment to supporting innovation in nuclear medicine and radiopharmacy. As the field of targeted alpha therapy continues to advance, LabLogic remains committed to helping shape the systems, standards, and technologies that will enable these promising treatments to reach patients safely and efficiently.
Access the editorial
You can read the full editorial by clicking the button below.
Acknowledgement for αccelerate.EU
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101173001 — Accelerate.EU. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe and IBA, Tetrakit and LabLogic.
Register for upcoming Alpha QC User Group at EANM
Attendees from LabLogic's Alpha QC User Group ahead of the 2026 SNMMI Annual Meeting in LA.
Vienna, Austria | Saturday 17 October, 2026
LabLogic has recently hosted events dedicated to the quality control of alpha therapeutics at our head office in the UK and at the 2026 SNMMI Annual Meeting. Partners from across industry and academia came together to help drive innovation in this important area. Following its success, we will be hosting another user groups ahead of this year's EANM Annual Congress.
What we’ll cover
- The ongoing development of 225Ac, 212Pb and 211At in Targeted Alpha Therapies
- Current research into delivering practical QC solutions
- Live demonstrations of radio-TLC and radio-HPLC tests
- Presentations from industry partners
Click the button below to register and secure your place.